Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: werner.lanthaler@evotec.com

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,580.006.70-0.08%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,530.3670.90-0.30%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,329.22168.750.45%
NZX 50 Index12,547.6948.81-0.39%
S&P 5005,802.8239.19-0.67%
S&P/ASX 2008,351.409.50-0.11%
SSE Composite Index3,360.9312.560.38%

Market Movers